AVENUE THERAPEUTICS, INC. financial data

Symbol
ATXI on OTC
Location
Bay Harbor Islands, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 35% % -14%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,183,558 shares 67%
Common Stock, Shares, Outstanding 3,183,558 shares 98%
Common Stock, Value, Issued $0 USD
Weighted Average Number of Shares Outstanding, Basic 3,183,558 shares 99%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $1,345,000 USD -81%
General and Administrative Expense $3,987,000 USD -16%
Operating Income (Loss) $3,928,000 USD 67%
Nonoperating Income (Expense) $32,000 USD -54%
Net Income (Loss) Attributable to Parent $683,000 USD 78%
Earnings Per Share, Basic -0.21 USD/shares 89%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $3,709,000 USD 43%
Assets $3,725,000 USD 42%
Liabilities, Current $1,422,000 USD 46%
Liabilities $1,422,000 USD 46%
Retained Earnings (Accumulated Deficit) $104,780,000 USD -3.7%
Stockholders' Equity Attributable to Parent $3,557,000 USD 36%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $2,303,000 USD 39%
Liabilities and Equity $3,725,000 USD 42%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 3,183,558 shares 98%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Preferred Stock, Shares Issued 250,000 shares 0%
Preferred Stock, Shares Authorized 2,000,000 shares 0%
Additional Paid in Capital $108,337,000 USD 4.5%
Preferred Stock, Shares Outstanding 250,000 shares 0%
Share-based Payment Arrangement, Expense $1,045,000 USD 2.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%